To decrease the incidence of chemotherapy-induced myelosuppression in patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen

For extensive-stage small cell lung cancer (ES-SCLC)

The First and Only Multilineage Myeloprotection Therapy

Proactively Help Protect Against Multiple Myelosuppressive Consequences

COSELA™ (trilaciclib) is administered prior to chemotherapy to help protect ES-SCLC patients against chemotherapy-induced myelosuppression. The Pivotal Study compared an etoposide/carboplatin + atezolizumab (E/P/A) regimen with COSELA vs without COSELA based on endpoints across multiple lineages, including:

  • Incidence and duration of severe neutropenia (primary endpoints)
  • Incidence of Grade 3/4 anemia and red blood cell (RBC) transfusions (secondary endpoints)
  • Rate of chemotherapy dose reductions (secondary endpoint)
See Study Design >

DATA FROM THE PIVOTAL STUDY (E/P/A):

SIGNIFICANT REDUCTIONS IN SEVERE NEUTROPENIA

SIGNIFICANTLY REDUCED THE INCIDENCE AND DURATION OF SEVERE NEUTROPENIA (PRIMARY ENDPOINTS)

  • 96% reduction in the incidence of severe neutropenia with COSELA (P<0.0001)*
  • 0 days of severe neutropenia with COSELA vs 4 days without COSELA in Cycle 1 (P<0.0001)

*Adjusted relative risk 0.038 (95% CI, 0.008, 0.195)

Mean difference -3.6 (95% CI, -4.9, -2.3)

See Neutropenia Data >

MYELOPROTECTIVE EFFICACY STUDIED IN THE RBC LINEAGE

INCIDENCE OF GRADE 3/4 ANEMIA AND RED BLOOD CELL (RBC) TRANSFUSIONS (SECONDARY ENDPOINTS)

  • The incidence of Grade 3/4 anemia was 28% without COSELA vs 19% with COSELA
  • The incidence of RBC transfusions was 21% without COSELA vs 13% with COSELA§

Adjusted relative risk 0.663 (95% CI, 0.336, 1.310)

§Adjusted relative risk 0.642 (95% CI, 0.294, 1.404)

See RBC Data >

Decreased Rate of Dose Reductions

DECREASED RATE OF DOSE REDUCTIONS (SECONDARY ENDPOINT)

The rate of all-cause chemotherapy dose reductions (events per 100 cycles) was significantly lower with COSELA: 2.1 vs 8.5 without COSELA (P=0.0195)

Adjusted relative risk 0.242 (95% CI, 0.079, 0.742)

See Dose Reduction Data >

INTEGRATED SAFETY ACROSS STUDIES

The most common adverse reactions (≥10%) were fatigue, hypocalcemia, hypokalemia, hypophosphatemia, aspartate aminotransferase increased, headache, and pneumonia.

See Safety Data >
Neutrophil cell Neutrophil cell Neutrophil cell Neutrophil cell

4 days without COSELA

REDUCTION IN DURATION OF SEVERE NEUTROPENIA

0 days with COSELA

proactive use reduced the incidence of SEVERE neutropenia by

96%*

Red blood cell Red blood cell Red blood cell

28% without COSELA

INCIDENCE OF GRADE 3/4 ANEMIA

19% with COSELA

PERCENTWITH DOSEREDUCTIONSOF ETOPOSIDE26% WITHOUTCOSELA6% WITHCOSELAPERCENT WITHDOSE REDUCTIONSOF CARBOPLATIN25% WITHOUTCOSELA2% WITHCOSELA

INDICATION: COSELA is indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer (ES-SCLC).

THE ONLY THERAPY THAT PROACTIVELY helps protect MULTIPLE BLOOD CELL LINEAGES

COSELA helps protect hematopoietic stem and progenitor cells (HSPCs), the source of multiple blood cell lineages. See the mechanism of action (MOA) of COSELA.

Watch the MOA Video